Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration.
作者信息
Du Repaire Théau, Vigne Petula, Guedon Amaury, Fanciullino Raphaelle, Gauthier-Villano Laurence, Peres Pierre Bertault, Pourroy Bertrand
机构信息
Pharmacy DepartmentLa Timone University Teaching HospitalMarseille, France.
Pharmacy DepartmentConception University Teaching HospitalMarseille, France.
出版信息
Am J Health Syst Pharm. 2017 Aug 15;74(16):1217-1218. doi: 10.2146/ajhp170111.
PMID:28790072
Abstract
摘要
相似文献
1
Visual compatibility of blinatumomab with selected drugs during simulated Y-site administration.在模拟Y型给药过程中，博纳吐单抗与选定药物的视觉相容性。
Am J Health Syst Pharm. 2017 Aug 15;74(16):1217-1218. doi: 10.2146/ajhp170111.
2
Visual compatibility of gallium nitrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm. 1993 Jun;50(6):1208-10.
3
4
How we infuse blinatumomab.我们如何输注博纳吐单抗。
Pediatr Blood Cancer. 2020 Sep;67(9):e28541. doi: 10.1002/pbc.28541. Epub 2020 Jun 23.
5
Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients.氢化可的松持续输注与危重症患者中使用的添加剂的 Y 型部位物理相容性。
Am J Health Syst Pharm. 2020 Jul 7;77(14):1144-1148. doi: 10.1093/ajhp/zxaa118.
6
Minimizing waste during preparation of blinatumomab infusions.
Am J Health Syst Pharm. 2016 Jan 15;73(2):19-20. doi: 10.2146/ajhp150420.
7
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.培美曲塞二钠在模拟Y型静脉给药过程中与其他药物的物理相容性。
Am J Health Syst Pharm. 2004 Nov 1;61(21):2289-93. doi: 10.1093/ajhp/61.21.2289.
8
Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.医疗保险针对博纳吐单抗的新技术附加支付计划的应用。
JAMA Oncol. 2016 Feb;2(2):165-6. doi: 10.1001/jamaoncol.2015.5359.
9
Blinatumomab infusion interruptions in pediatric patients rarely lead to readmission.儿童患者中断blinatumomab 输注很少导致再入院。
Pediatr Blood Cancer. 2024 Oct;71(10):e31223. doi: 10.1002/pbc.31223. Epub 2024 Jul 25.
10
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.双特异性 T 细胞衔接器（BiTE）抗体构建药物blinatumomab 治疗复发/难治性非霍奇金淋巴瘤患者：I 期研究的最终结果。
J Clin Oncol. 2016 Apr 1;34(10):1104-11. doi: 10.1200/JCO.2014.59.1586. Epub 2016 Feb 16.
引用本文的文献
1
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study.雷莫司琼3.0μg/mL与地塞米松（0.05、0.1、0.2mg/mL）在输液中的联合应用：理化稳定性研究
Dose Response. 2024 Oct 14;22(4):15593258241293220. doi: 10.1177/15593258241293220. eCollection 2024 Oct-Dec.
Zotero 插件